Author

V. Tajiknia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

K. E. Huntington· 2 shared L. Zhang· 2 shared M. Pinho-Schwermann· 2 shared P. R. Srinivasan· 2 shared W. S. El-Deiry· 2 shared A. De Souza· 1 shared A. George· 1 shared B. A. Carneiro· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

K. E. Huntington

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 15, 2023

Androgen receptor signaling blockade enhances NK cell-mediated killing of prostate cancer cells and sensitivity to NK cell checkpoint blockade

M. Pinho-Schwermann, C. Purcell, L. Carlsen…·W. S. El-Deiry

This study shows that androgen receptor inhibitors enhance NK cell-mediated killing of prostate cancer cells and sensitivity to NKG2A checkpoint blockade by upregulating HLA-E expression.

DOI 10.1101/2023.11.15.567201

humanmouse

𝕏 PostBluesky

Cancer BiologybioRxivSep 13, 2023

Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation

V. Tajiknia, M. Pinho-Schwermann, P. R. Srinivasan…·W. S. El-Deiry

This study shows that MRTX1133, a KRAS G12D inhibitor, synergizes with 5-FU or ONC212 to reduce tumor cell viability and pERK in CRC and pancreatic cancer cells, regardless of KRAS mutation status.

DOI 10.62347/dvxl1377

humanproteomics

𝕏 PostBluesky